Who owns Pieris Pharmaceuticals?
- Ticker: PIRS
- CUSIP Number: 720795103
Tip: Access positions for across all investors
Analyze quarterly positions in Pieris Pharmaceuticals with up to 7 years of data, all consolidated into one spreadsheet
Download as csv Download as ExcelTop investors of Pieris Pharmaceuticals stock
Who bought or sold Pieris Pharmaceuticals this quarter?
Fund or Company Name | Shares Held | Valued At | Change in Shares | As Of | Actions |
---|---|---|---|---|---|
BVF | 21M | $3.8M | 0% | Dec 2023 |
|
Lynx1 Capital Management | 9.8M | $1.8M | 0% | Dec 2023 |
|
Citadel Advisors | 1.3M | $229k | 108% | Dec 2023 |
|
BlackRock | 1.0M | $309k | -1% | Sep 2023 |
|
Acadian Asset Management | 962k | $286k | 65% | Sep 2023 |
|
Vanguard Group | 907k | $165k | -12% | Dec 2023 |
|
Geode Capital Management | 761k | $227k | 15% | Sep 2023 |
|
CM Management | 750k | $137k | 15% | Dec 2023 |
|
Renaissance Technologies | 381k | $114k | 3% | Sep 2023 |
|
State Street Corporation | 223k | $66k | 0% | Sep 2023 |
|
Millennium Management | 167k | $30k | -26% | Dec 2023 |
|
Northern Trust | 138k | $41k | 0% | Sep 2023 |
|
Prudential Financial | 110k | $33k | 834% | Sep 2023 |
|
Virtu Financial | 90k | $16k | 100% | Dec 2023 |
|
Citigroup | 89k | $16k | 0% | Dec 2023 |
|
Two Sigma Investments | 41k | $7.4k | -3% | Dec 2023 |
|
Bank of New York Mellon | 40k | $7.3k | 0% | Dec 2023 |
|
NorthStar Asset Management | 39k | $7.1k | 100% | Dec 2023 |
|
Two Sigma Advisers | 35k | $6.3k | 42% | Dec 2023 |
|
Tower Research Capital | 31k | $9.2k | 26% | Sep 2023 |
|
Raymond James & Associates | 30k | $5.5k | 0% | Dec 2023 |
|
NJ State Employees Deferred Compensation Plan | 30k | $5.5k | 0% | Dec 2023 |
|
Goldman Sachs Group | 23k | $4.1k | 0% | Dec 2023 |
|
Baader Bank | 20k | $2.7k | 100% | Dec 2023 |
|
Commerce Bank N A | 20k | $3.6k | 0% | Dec 2023 |
|
Kestra Advisory Services | 18k | $3.2k | 100% | Dec 2023 |
|
Two Sigma Securities | 15k | $2.8k | -15% | Dec 2023 |
|
Hudson Valley Investment Advisors | 14k | $2.4k | 0% | Dec 2023 |
|
HPM Partners | 10k | $1.9k | 100% | Dec 2023 |
|
Us Bancorp | 10k | $1.9k | 0% | Dec 2023 |
|
Morgan Stanley | 8.2k | $2.4k | 0% | Sep 2023 |
|
Group One Trading | 6.7k | $2.0k | 0% | Sep 2023 |
|
UBS Group | 6.3k | $1.1k | -86% | Dec 2023 |
|
Barclays | 5.0k | $1.0k | 0% | Dec 2023 |
|
Wells Fargo & Company | 4.8k | $866.502000 | -17% | Dec 2023 |
|
Cutler | 4.5k | $0 | 0% | Dec 2023 |
|
1620 Investment Advisors | 4.4k | $318k | 100% | Dec 2023 |
|
Jpmorgan Chase & Co | 2.0k | $358.327800 | -98% | Dec 2023 |
|
Rhumbline Advisers | 1.9k | $339.052200 | 0% | Dec 2023 |
|
Truvestments Capital | 1.1k | $333.984000 | 0% | Sep 2023 |
|
Royal Bank of Canada | 572.00 | $0 | -82% | Dec 2023 |
|
Advisor Group Holdings | 516.00 | $94.015200 | 0% | Dec 2023 |
|
Hanson McClain Advisors | 350.00 | $64.015000 | 0% | Dec 2023 |
|
Bank of America Corporation | 145.00 | $25.998500 | 0% | Dec 2023 |
|
FMR | 0 | $0 | -100% | Sep 2023 |
|
Who sold out of Pieris Pharmaceuticals?
Fund or Company Name | Date Sold | Shares Held | Valued At |
---|---|---|---|
Aquilo Capital Management | Sep 2023 | 3.3M | $984k |
Silverarc Capital Management | Jun 2023 | 961k | $159k |
Hrt Financial | Sep 2023 | 18k | $5.0k |
National Asset Management | Sep 2023 | 17k | $5.1k |
Wealth Effects | Sep 2023 | 12k | $3.5k |
Oppenheimer & Co | Jun 2023 | 11k | $1.7k |
Tower View Investment Management & Research | Sep 2023 | 1.0k | $0 |